• Something wrong with this record ?

Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation

L. Nocera, C. Collà Ruvolo, LF. Stolzenbach, M. Wenzel, Z. Tian, A. Larcher, U. Capitanio, V. Mirone, D. Tilki, FKH. Chun, A. Kapoor, SF. Shariat, F. Saad, F. Montorsi, A. Briganti, PI. Karakiewicz

. 2022 ; 8 (1) : 182-190. [pub] 20210227

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22019527

BACKGROUND: For patients with nonmetastatic renal cell carcinoma (nmRCC) treated with nephrectomy, prediction of cancer-specific mortality (CSM) by T stage and substage has not been validated for the separate histological subtypes. OBJECTIVE: To investigate the ability of pathological T stage and substage to predict CSM for patients with clear-cell, papillary, or chromophobe nmRCC treated with nephrectomy. DESIGN, SETTING, AND PARTICIPANTS: Using the SEER database for 2004-2016, we identified 87 149 patients with T1-4 N0/X M0 nmRCC treated with nephrectomy for the clear-cell (65 715; 75.4%), papillary (14 587; 16.7%), or chromophobe (6847; 7.9%) histological subtype. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier plots and Cox regression models were used to estimate CSM. RESULTS AND LIMITATIONS: For all three histological subtypes, patients with T1a-T3a disease exhibited more favorable CSM than patients with T3b-T4 RCC. For clear-cell RCC, there were clinically meaningful and statistically significant differences for virtually all intergroup comparisons among T1a-T3a stages. For papillary T1a-T3a RCC, clinically meaningful differences disappeared, although the statistical significance remained. For chromophobe T1a-T3a RCC, no clinically meaningful or statistically significant differences were observed. For all three histological subtypes, patients with T3b-T4 RCC exhibited virtually uniformly unfavorable CSM, with no clinically meaningful intergroup CSM differences. CONCLUSION: The use of T stage and substage for stratification of patients with nmRCC treated with nephrectomy revealed differences in CSM among T1a-T3a cases, but not T3b-T4. The magnitude of the CSM difference was greatest for clear-cell, intermediate for papillary, and marginal for chromophobe RCC. PATIENT SUMMARY: For patients with kidney cancer, the stage of their disease assessed after surgery on the affected kidney can predict how likely they are to die from their cancer. This prediction varies for different subtypes of kidney cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019527
003      
CZ-PrNML
005      
20220804135734.0
007      
ta
008      
220720s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euf.2021.02.009 $2 doi
035    __
$a (PubMed)33653677
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Nocera, Luigi $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: nocera.luigi@hsr.it
245    10
$a Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation / $c L. Nocera, C. Collà Ruvolo, LF. Stolzenbach, M. Wenzel, Z. Tian, A. Larcher, U. Capitanio, V. Mirone, D. Tilki, FKH. Chun, A. Kapoor, SF. Shariat, F. Saad, F. Montorsi, A. Briganti, PI. Karakiewicz
520    9_
$a BACKGROUND: For patients with nonmetastatic renal cell carcinoma (nmRCC) treated with nephrectomy, prediction of cancer-specific mortality (CSM) by T stage and substage has not been validated for the separate histological subtypes. OBJECTIVE: To investigate the ability of pathological T stage and substage to predict CSM for patients with clear-cell, papillary, or chromophobe nmRCC treated with nephrectomy. DESIGN, SETTING, AND PARTICIPANTS: Using the SEER database for 2004-2016, we identified 87 149 patients with T1-4 N0/X M0 nmRCC treated with nephrectomy for the clear-cell (65 715; 75.4%), papillary (14 587; 16.7%), or chromophobe (6847; 7.9%) histological subtype. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier plots and Cox regression models were used to estimate CSM. RESULTS AND LIMITATIONS: For all three histological subtypes, patients with T1a-T3a disease exhibited more favorable CSM than patients with T3b-T4 RCC. For clear-cell RCC, there were clinically meaningful and statistically significant differences for virtually all intergroup comparisons among T1a-T3a stages. For papillary T1a-T3a RCC, clinically meaningful differences disappeared, although the statistical significance remained. For chromophobe T1a-T3a RCC, no clinically meaningful or statistically significant differences were observed. For all three histological subtypes, patients with T3b-T4 RCC exhibited virtually uniformly unfavorable CSM, with no clinically meaningful intergroup CSM differences. CONCLUSION: The use of T stage and substage for stratification of patients with nmRCC treated with nephrectomy revealed differences in CSM among T1a-T3a cases, but not T3b-T4. The magnitude of the CSM difference was greatest for clear-cell, intermediate for papillary, and marginal for chromophobe RCC. PATIENT SUMMARY: For patients with kidney cancer, the stage of their disease assessed after surgery on the affected kidney can predict how likely they are to die from their cancer. This prediction varies for different subtypes of kidney cancer.
650    12
$a karcinom z renálních buněk $x patologie $7 D002292
650    _2
$a lidé $7 D006801
650    _2
$a ledviny $x patologie $7 D007668
650    12
$a nádory ledvin $x patologie $7 D007680
650    _2
$a nefrektomie $7 D009392
650    _2
$a proporcionální rizikové modely $7 D016016
655    _2
$a časopisecké články $7 D016428
700    1_
$a Collà Ruvolo, Claudia $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Department of Urology, University of Naples Federico II, Naples, Italy
700    1_
$a Stolzenbach, Lara F $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Wenzel, Mike $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Tian, Zhe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
700    1_
$a Larcher, Alessandro $u Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Capitanio, Umberto $u Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Mirone, Vincenzo $u Department of Urology, University of Naples Federico II, Naples, Italy
700    1_
$a Tilki, Derya $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Chun, Felix K H $u Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany
700    1_
$a Kapoor, Anil $u Division of Urology, Department of Surgery, Juravinski Cancer Centre, McMaster University, Hamilton, Canada
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Departments of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
700    1_
$a Saad, Fred $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
700    1_
$a Montorsi, Francesco $u Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Briganti, Alberto $u Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
773    0_
$w MED00193513 $t European urology focus $x 2405-4569 $g Roč. 8, č. 1 (2022), s. 182-190
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33653677 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135728 $b ABA008
999    __
$a ok $b bmc $g 1822929 $s 1170770
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 8 $c 1 $d 182-190 $e 20210227 $i 2405-4569 $m European urology focus $n Eur Urol Focus $x MED00193513
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options